CD8A and neoplasm: Furthermore, APC-presented antigens are always presented and processed alongside MHC II, implying that CD8+ T cell-induced cellular immunity is not activated.203,204 To overcome the problems, Xie et al. created a tumor cell membrane-coated biomimetic cancer vaccine (A/M/C-MNC).205 CpG-ODN, a Toll-like receptor (TLR) agonist, was adsorbed on the core of Fe3O4 MNCs (C-MNCs).